As JAK-STAT signaling is a potential target in many T cell lymphoma, a phase 2 biomarker-driven trial investigating ruxolitinib, a JAK inhibitor, was initiated. The gene discussed is SOAT1; the disease is T-cell non-Hodgkin lymphoma.